vs

Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Community Healthcare Trust Inc is the larger business by last-quarter revenue ($30.9M vs $19.6M, roughly 1.6× STANDARD BIOTOOLS INC.). Community Healthcare Trust Inc runs the higher net margin — 46.6% vs -177.4%, a 224.0% gap on every dollar of revenue. On growth, Community Healthcare Trust Inc posted the faster year-over-year revenue change (5.6% vs -11.5%). Community Healthcare Trust Inc produced more free cash flow last quarter ($35.9M vs $-23.1M). Over the past eight quarters, Community Healthcare Trust Inc's revenue compounded faster (2.7% CAGR vs -12.2%).

Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CHCT vs LAB — Head-to-Head

Bigger by revenue
CHCT
CHCT
1.6× larger
CHCT
$30.9M
$19.6M
LAB
Growing faster (revenue YoY)
CHCT
CHCT
+17.1% gap
CHCT
5.6%
-11.5%
LAB
Higher net margin
CHCT
CHCT
224.0% more per $
CHCT
46.6%
-177.4%
LAB
More free cash flow
CHCT
CHCT
$59.0M more FCF
CHCT
$35.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CHCT
CHCT
Annualised
CHCT
2.7%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CHCT
CHCT
LAB
LAB
Revenue
$30.9M
$19.6M
Net Profit
$14.4M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
46.6%
-177.4%
Revenue YoY
5.6%
-11.5%
Net Profit YoY
687.6%
-28.8%
EPS (diluted)
$0.52
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHCT
CHCT
LAB
LAB
Q4 25
$30.9M
Q3 25
$31.1M
$19.6M
Q2 25
$29.1M
$21.8M
Q1 25
$30.1M
$40.8M
Q4 24
$29.3M
Q3 24
$29.6M
$22.1M
Q2 24
$27.5M
$22.5M
Q1 24
$29.3M
$45.5M
Net Profit
CHCT
CHCT
LAB
LAB
Q4 25
$14.4M
Q3 25
$1.6M
$-34.7M
Q2 25
$-12.6M
$-33.5M
Q1 25
$1.6M
$-26.0M
Q4 24
$1.8M
Q3 24
$1.7M
$-26.9M
Q2 24
$-10.4M
$-45.7M
Q1 24
$3.7M
$-32.2M
Gross Margin
CHCT
CHCT
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
CHCT
CHCT
LAB
LAB
Q4 25
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q4 24
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Net Margin
CHCT
CHCT
LAB
LAB
Q4 25
46.6%
Q3 25
5.3%
-177.4%
Q2 25
-43.2%
-153.7%
Q1 25
5.3%
-63.8%
Q4 24
6.3%
Q3 24
5.9%
-122.0%
Q2 24
-37.9%
-203.3%
Q1 24
12.5%
-70.6%
EPS (diluted)
CHCT
CHCT
LAB
LAB
Q4 25
$0.52
Q3 25
$0.03
$-0.09
Q2 25
$-0.50
$-0.09
Q1 25
$0.03
$-0.07
Q4 24
$0.04
Q3 24
$0.04
$-0.07
Q2 24
$-0.42
$-0.12
Q1 24
$0.11
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHCT
CHCT
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$3.3M
$129.4M
Total DebtLower is stronger
$532.2M
Stockholders' EquityBook value
$429.4M
$399.7M
Total Assets
$990.8M
$539.6M
Debt / EquityLower = less leverage
1.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHCT
CHCT
LAB
LAB
Q4 25
$3.3M
Q3 25
$3.4M
$129.4M
Q2 25
$4.9M
$158.6M
Q1 25
$2.3M
$150.9M
Q4 24
$4.4M
Q3 24
$2.8M
$210.6M
Q2 24
$734.0K
$269.8M
Q1 24
$3.8M
$287.1M
Total Debt
CHCT
CHCT
LAB
LAB
Q4 25
$532.2M
Q3 25
$530.1M
Q2 25
$500.1M
Q1 25
$496.0M
Q4 24
$486.0M
Q3 24
$473.7M
$55.2M
Q2 24
$457.6M
$55.1M
Q1 24
$442.3M
$55.0M
Stockholders' Equity
CHCT
CHCT
LAB
LAB
Q4 25
$429.4M
Q3 25
$426.8M
$399.7M
Q2 25
$437.8M
$424.5M
Q1 25
$461.3M
$454.6M
Q4 24
$476.0M
Q3 24
$477.2M
$489.3M
Q2 24
$497.8M
$510.3M
Q1 24
$511.6M
$577.3M
Total Assets
CHCT
CHCT
LAB
LAB
Q4 25
$990.8M
Q3 25
$987.3M
$539.6M
Q2 25
$966.3M
$557.0M
Q1 25
$985.1M
$579.6M
Q4 24
$992.6M
Q3 24
$981.8M
$681.5M
Q2 24
$983.2M
$708.7M
Q1 24
$982.7M
$777.7M
Debt / Equity
CHCT
CHCT
LAB
LAB
Q4 25
1.24×
Q3 25
1.24×
Q2 25
1.14×
Q1 25
1.08×
Q4 24
1.02×
Q3 24
0.99×
0.11×
Q2 24
0.92×
0.11×
Q1 24
0.86×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHCT
CHCT
LAB
LAB
Operating Cash FlowLast quarter
$56.4M
$-22.2M
Free Cash FlowOCF − Capex
$35.9M
$-23.1M
FCF MarginFCF / Revenue
116.0%
-118.1%
Capex IntensityCapex / Revenue
66.3%
4.5%
Cash ConversionOCF / Net Profit
3.91×
TTM Free Cash FlowTrailing 4 quarters
$62.8M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHCT
CHCT
LAB
LAB
Q4 25
$56.4M
Q3 25
$12.7M
$-22.2M
Q2 25
$13.8M
$-20.7M
Q1 25
$14.4M
$-30.3M
Q4 24
$58.9M
Q3 24
$13.8M
$-27.9M
Q2 24
$16.7M
$-39.0M
Q1 24
$12.6M
$-62.5M
Free Cash Flow
CHCT
CHCT
LAB
LAB
Q4 25
$35.9M
Q3 25
$7.6M
$-23.1M
Q2 25
$9.6M
$-22.6M
Q1 25
$9.7M
$-35.3M
Q4 24
$34.2M
Q3 24
$6.7M
$-30.1M
Q2 24
$9.5M
$-41.0M
Q1 24
$7.5M
$-63.3M
FCF Margin
CHCT
CHCT
LAB
LAB
Q4 25
116.0%
Q3 25
24.6%
-118.1%
Q2 25
32.9%
-103.6%
Q1 25
32.3%
-86.6%
Q4 24
116.9%
Q3 24
22.5%
-136.4%
Q2 24
34.7%
-182.2%
Q1 24
25.7%
-138.9%
Capex Intensity
CHCT
CHCT
LAB
LAB
Q4 25
66.3%
Q3 25
16.3%
4.5%
Q2 25
14.5%
8.7%
Q1 25
15.6%
12.4%
Q4 24
84.1%
Q3 24
24.2%
10.2%
Q2 24
26.1%
8.6%
Q1 24
17.4%
1.7%
Cash Conversion
CHCT
CHCT
LAB
LAB
Q4 25
3.91×
Q3 25
7.76×
Q2 25
Q1 25
9.06×
Q4 24
32.14×
Q3 24
7.92×
Q2 24
Q1 24
3.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHCT
CHCT

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons